Full-Time

Campaign Excellence Manager

Posted on 5/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Growth & Marketing (1)
Required Skills
Veeva
Agile
Salesforce
Data Analysis
Requirements
  • Doctorate Degree
  • Master’s degree with 4 - 6 years of experience in Campaign Management or related field
  • Bachelor’s degree with 6 - 8 years of experience in Campaign Management or related field
  • Diploma with 10 - 12 years of experience in Campaign Management, IT or related field.
Responsibilities
  • Omnichannel Campaign Design and ownership of the Omnichannel Design toolkit – The Campaign Excellence Manager is responsible for building capabilities in local brand teams to enable developing engaging omnichannel customer experiences. In this process, the Campaign Excellence Manager facilitates robust campaign design conversations by bringing in key inputs including brand strategy, customer journey leverage / intervention points, key segments with digital affinities and preferences, behavioral objectives per segment, segment-specific insights, hypotheses and drivers / barriers message and content plans.
  • Campaign Analysis – analyzing the performance of marketing campaigns across various markets, looking at performance of channels and content, extracting actionable insights, and contributing to the optimization of our campaigns.
  • High-level understanding of both strategic and tactical components of campaign planning, advise strategic collaborators on how to leverage marketing technology platforms such as Salesforce Marketing Cloud, VEEVA Sales CRM, Websites and 3rd Party Channel Partners (into the campaign planning process.).
  • Workshop Facilitation – Facilitate workshops using the Customer Experience design process to develop omnichannel campaigns – including development of campaign objectives, target customer groups, message flows, and customer journeys.
  • Project Management – The Campaign Excellence Manager maximises the campaign design process for operational planning requests from the brand to coordinate the execution of the Customer Experience. E.g., they coordinates with brand leads to prepare campaign calendar considering other relevant events (such as medical conferences, new indications for product, etc.). Apply Agile methodologies to coordinate campaign development and deployment details with cross-functional collaborators.
  • Campaign Execution Preparation – Ensure operational readiness of campaigns with the Global Service Center, DTI (Digital Technology & Innovation), Digital Operations and Global Data and Analytics partners.
  • Campaign Metrics (Cross-Channel Campaign Measurement & Reporting) - The Campaign Excellence Manager facilitates the definition and documentation of how the success of the campaign will be measured with the Commercial Data and Analytics Data Sciences team. The Campaign Ops Manager also facilitates the design of the Tagging Strategy to enable reporting, measurement and campaign optimization.
Desired Qualifications
  • Strong leadership, collaborating, and influencing skills with a demonstrated ability to achieve goals and results in a highly matrixed environment.
  • Experience facilitating conversations and driving decisions in cross-functional settings.
  • Strong consultative problem-solving skills.
  • Solid understanding of metadata and tagging methodologies for effective tracking of digital marketing campaigns.
  • Solid understanding of Marketing Automation Platforms and proficiency in defining requirements to implement in automation platforms. Direct experience with Salesforce Marketing Cloud.
  • Able to work without guidance, take full ownership of campaigns, deal proactively with queries, present solutions, and contribute.
  • Ability to effectively present ideas and document complex concepts and processes in both written and oral communication.
  • Excellent interpersonal and organizational skills.
  • Thrive in a fast-changing environment.
  • 5+ years of techno-functional experience in Digital Marketing Operations, Email marketing, SFMC ecosystem, CMS, CRM, Analytics, and Agile.
  • Demonstrated experience with Marketing Automation platforms (SFMC certification is a plus)
  • Good understanding of data flow and management.
  • Experience working with Brand teams and Senior business collaborators. Also, in working on highly complex projects which involve cross-channel integration, solution designing, implementation and support.
  • Ability to design and consult on end to end journeys involving multiple channels
  • Strong teammate to actively coordinate with different collaborators from Amgen and Global Service Center.
  • Ability to understand the big picture when it comes to related platforms and integrations.
  • Ability to make data-driven decisions around digital marketing using reporting tools like Tableau.
  • Use the latest standard methodology learning from the industry to help Customers ensure that marketing campaigns and solutions are fully integrated and fine-tuned via data-driven insights.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.